Sequential Models – When Are They the Right Choice?
Author(s)
Speakers: Simone Rivolo, PhD, Evidera, London, LON, UK Ágnes Benedict, MSc, MA, Evidera, London, LON, UK
Presentation Documents
Sequential modelling has been used in health technology appraisals, clinical pathway and strategic models to support payer, clinical and manufacturer decision-making across several disease areas, including autoimmune diseases and oncology. Building sequential models can shed light on questions that simple treatment line specific models cannot, including the clinically and economically optimal positioning of a therapy in a treatment sequence especially in disease areas with therapies indicated across several lines. These models, however, can prove technically challenging to implement, require comprehensive clinical data sources, and interpretation of results of sequencing models are often more demanding than for line specific models.
During this presentation we will provide an overview of the reasons to consider and develop sequential models. We will outline the decision problems, key challenges and circumstances under which sequential modelling is likely a good investment, and also discuss when this type of modelling may not be the right approach. Across the presentation, multiple recent applications will be leveraged.
Learning Objectives:
- Consider what decision problems would require true sequential modelling and cannot be answered by a simpler approach – from a clinical, manufacturer and payer point of view
- Understand the sweet spot for sequential models from the perspective of the treatment landscape for a given therapy and therapy portfolio
- Suggest methods for executing sequential models – leveraging other pieces of standardly generated evidence
Conference/Value in Health Info
2022-11, ISPOR Europe 2022, Vienna, Austria
Code
120